We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+21.05%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$340M
AUM Growth
-$154M
Cap. Flow
-$164M
Cap. Flow %
-48.19%
Top 10 Hldgs %
53.86%
Holding
71
New
18
Increased
9
Reduced
13
Closed
25

Top Buys

1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20.8M
2
BLUE
bluebird bio
BLUE
+$18.5M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$11M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.97M

Top Sells

1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$20.2M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$17.5M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.7M
4
VTRS icon
Viatris
VTRS
+$14.4M
5
IMMU
Immunomedics Inc
IMMU
+$12.1M

Sector Composition

1 Healthcare 84.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
26
DELISTED
Audentes Therapeutics, Inc
BOLD
$4.78M 1.41%
+125,000
New +$4.63M
IOVA icon
27
Iovance Biotherapeutics
IOVA
$2.23B
$4.61M 1.36%
360,000
-640,000
-64% -$9.35M
KURA icon
28
Kura Oncology
KURA
$964M
$4.19M 1.23%
+230,000
New +$3.9M
BDSI
29
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.16M 1.23%
+1,411,247
New +$3.35M
GYRE icon
30
Gyre Therapeutics
GYRE
$675M
$4.14M 1.22%
47,333
-12,667
-21% -$2.22M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$4.07M 1.2%
+185,000
New +$4.25M
NEOS
32
DELISTED
Neos Therapeutics, Inc
NEOS
$3.75M 1.1%
600,000
– –
LCI
33
DELISTED
Lannett Company, Inc.
LCI
$3.4M 1%
62,500
– –
GNCA
34
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.02M 0.89%
+440,625
New +$3.3M
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
$2.76M 0.81%
450,000
-400,000
-47% -$2.81M
ANAB icon
36
AnaptysBio
ANAB
$1.72B
$1.11M 0.33%
15,700
+6,700
+74% +$562K
LRMR icon
37
Larimar Therapeutics
LRMR
$384M
$1.05M 0.31%
+8,522
New +$724K
ACOR
38
DELISTED
Acorda Therapeutics
ACOR
$947K 0.28%
+275
New +$842K
PBYI icon
39
Puma Biotechnology
PBYI
$434M
$828K 0.24%
+14,000
New +$811K
PDSB icon
40
PDS Biotechnology
PDSB
$41.1M
$773K 0.23%
+37,540
New +$783K
MOTS
41
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$719K 0.21%
333
– –
TGTX icon
42
TG Therapeutics
TGTX
$8.4B
$684K 0.2%
52,000
-248,000
-83% -$3.41M
SPPI
43
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$608K 0.18%
+29,000
New +$537K
XBI icon
44
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$525K 0.15%
5,000
-3,773
-43% -$347K
LCI
45
CALL
DELISTED
Lannett Company, Inc.
LCI
$520K 0.15%
+500
New +$31.5K
BHVN
46
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$122K 0.04%
2,000
-73,100
-97% -$2.32M
BPMC
47
DELISTED
Blueprint Medicines
BPMC
– –
-120,000
Closed -$11M
CPRX icon
48
Catalyst Pharmaceutical
CPRX
– –
-550,000
Closed -$1.31M
DBVT
49
DBV Technologies
DBVT
$870M
– –
-10,000
Closed -$2.31M
FOLD
50
DELISTED
Amicus Therapeutics
FOLD
– –
-750,000
Closed -$11.3M
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Ghost Tree Capital held 71 positions worth $340M, down 31% from $494M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Ghost Tree Capital withdrew a net $164M in Q2 2018, closing 25 positions and reducing 13 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $17.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 63% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Alnylam Pharmaceuticals worth $20.7M.

  • Ghost Tree Capital's largest Q2 2018 buy was Alnylam Pharmaceuticals: 210,000 shares worth $20.7M.
  • Ghost Tree Capital added most to PTC Therapeutics in Q2 2018, an estimated $14.8M increase.
  • Ghost Tree Capital's biggest Q2 2018 reduction was Endocyte, Inc. Common Stock, cutting an estimated $20.2M.
  • Ghost Tree Capital fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018, selling an estimated $17.5M.
  • Ghost Tree Capital's ten largest holdings make up 54% of its $340M portfolio in Q2 2018.
  • Ghost Tree Capital opened 18 new positions and closed 25 in Q2 2018.
  • Ghost Tree Capital's portfolio value fell 31% quarter-over-quarter to $340M.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.